• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

    3/12/24 8:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care
    Get the next $NURO alert in real time by email
    • NURO stock price has declined 99% since its IPO
    • Gozani has received compensation of over $10 million since the IPO
    • Gozani was charged by the FTC for various wrongdoings at NURO
    • Gozani apparently personally paid the FTC $4 million as part of a settlement
    • Gozani barely owns any NURO shares
    • NURO continues to sell stock significantly below its net cash value

    NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Earlier today Echo Lake Capital sent a letter to the Board of Directors of Neurometrix, Inc. (NASDAQ:NURO). The letter listed the top ten reasons why the Board should immediately fire Shai Gozani, the company's longstanding Chairman and CEO. The reasons include (i) NURO's stock price has declined 99% since the IPO, (ii) while shareholders have suffered massive losses, Gozani has received over $10 million of compensation, (iii) Gozani was charged by the Federal Trade Commission for various wrongdoings at NURO, (iv) Gozani apparently personally paid $4 million to the FTC as part of a settlement, and (v) Gozani's decision to dilute shareholders by having NURO issue shares at prices significantly below net cash.

    The letter also questions why the Board (whose members include a stand up comedian, a practicing doctor, and a board director of two other public companies (Performant Financial Corp. and American Oncology Network Inc.)), continue to support Gozani considering his performance over the past twenty years.

    A full copy of the letter can be found below:

    CONTACT:
    Ephraim Fields
    [email protected]

    To:

    Shai Gozani - Chairman and CEO

    Bradley Fluegel - Board Director at Performant Financial Corp. and American Oncology Network Inc.

    David E. Goodman - Practicing Doctor in Novato, CA

    Nancy E. Katz - "Consultant"

    David Van Avermaete - Stand Up Comedian

    Shai Gozani is the worst Chairman/CEO we have ever seen…and we've a lot of them.

    You collectively are among the worst Board of Directors we have ever seen. Even though NURO's long-suffering shareholders continue to lose money, you continue to enrich yourselves at shareholders' expense while also inexcusably continuing to support Mr. Gozani (despite his well-established track record of destroying shareholder value). We are deeply concerned about your repeated failures to act in shareholders' best interests. Furthermore, having closely analyzed your backgrounds and professional experiences we question why any public company would select you to serve as a board member....but these topics can be addressed in subsequent letters.

    Since you apparently believe Mr. Gozani has been doing a good job, we've prepared a list of the TOP 10 reasons why we believe he should be fired immediately:

    1) Stock price declined 99% since IPO in 2004.
    Gozani has been NURO's Chairman and CEO since its IPO and since that time NURO's stock price has declined 99% (adjusted for reverse stock splits). We don't know many CEOs who have kept their jobs after destroying so much shareholder value.
    2) Received over $10 mm of compensation since IPO.
    Since the IPO Gozani has received (aka the Board has given him) compensation exceeding $10 million. We're not sure what he has done to deserve so much compensation and can only wonder how much you would have paid him had NURO's stock price only declined 50% instead of 99%.
    3) Personally charged by the Federal Trade Commission for actions at NURO.
    In 2020 the FTC claimed Gozani (among other things) engaged in "unlawful acts and practices repeatedly over a period of more than four years, continued their unlawful acts or practices despite knowledge of complaints that advertising claims for Quell were not substantiated and went beyond claims the FDA allowed for similar devices, and continued such deceptive advertising unabated until FTC staff notified them it would recommend law enforcement action." We encourage you to read the entire FTC complaint which includes additional damaging allegations.
    4) Apparently personally paid the FTC $4 million as part of a settlement.
    We can only imagine the level of incriminating evidence the FTC had against Gozani that motivated him to apparently personally pay the FTC $4 million to settle this matter. More importantly, we strongly believe that Gozani's actions in this matter caused severe financial, operational and reputational damage to NURO and its shareholders.
    5) Approves of NURO issuing stock at massive discount to net cash.
    We find it inexcusable that NURO has been selling stock at prices dramatically below its net cash per share. We see no justification for these equity issuances especially since NURO already has a significant amount of net cash. Year to date Nuro has sold over 460,000 shares at an average price of $3.40, even though the company had $11.80 of net cash per share as of December 31, 2023. How on earth can you or Gozani justify this? We have NEVER seen a company sell stock at such a large discount to its net cash. Furthermore, considering how much shareholder value Gozani has destroyed, we wonder why you expect that he will do a good job allocating the additional capital NURO is raising.
    6) Barely owns any NURO shares.
    Despite being NURO's founder, Gozani owns only approximately 10,000 NURO shares. These shares have a market value of only $40,000 and represent 0.5% of the company's shares outstanding. Gozani's lack of personal investment in NURO shares may explain why he endorses such value destroying initiatives such as selling stock significantly below net cash. We think it reflects very poorly on a CEO when he owns so little stock in his own company.
    7) Refuses to speak with a large NURO shareholder.
    We are NURO's 2nd largest shareholder (and own multiples more stock than does the entire Board combined). We have been trying to speak to Gozani since late February (before we filed our Schedule 13D) but he has not responded to us. We believe part of a CEO's job is to engage with shareholders, not avoid them.
    8) Has taken compensation worth almost 2x NURO's equity market cap.
    The $10 million of compensation Gozani has taken from NURO (and its shareholders) is almost 2x greater than NURO's equity market cap (as of December 31, 2023). If you didn't think paying Gozani $10 million was excessive considering his absolute performance, what do you think of his compensation on a relative basis?
    9) Believes a $5.5 million market cap company should remain public.
    At the end of 2023, NURO had an equity market of only $5.5 million, making it one of the smallest publicly traded companies in the United States. Most sophisticated board members and investors we know believe that companies this small should not remain public (for many reasons including the relatively high costs of remaining public). On the other hand, Gozani apparently believes that NURO should remain public…since he is paid by NURO but owns very few shares in the company, we understand why he may be financially motivated to have NURO remain public, regardless of what happens to its stock price.
    10) Ask some former NURO shareholders.
    We believe that almost every institutional investor that NURO has had over the past 20 years has lost confidence in Gozani. If the nine reasons we listed above haven't convinced you to fire Gozani, we suggest you speak with some of NURO's former investors to learn why they dumped their shares and what they think of Gozani.

    None of what we have written in this letter should be new to you, nor should the public criticism you've received from the company's largest shareholder, RS Fund LP. We think it is shameful that the company's two largest shareholders have to publicly write to you in order to protect the value of their investment. If you really want anyone to believe you are fulfilling your fiduciary responsibilities and acting in the best interests of shareholders, we believe you should immediately (i) fire Gozani, (ii) cancel the ATM offering and (iii) liquidate the company.

    Sincerely,

    Ephraim Fields
    Echo Lake Capital

    SOURCE: Echo Lake Capital



    View the original press release on accesswire.com

    Get the next $NURO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NURO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NURO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

    ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the "Merger") with NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chroni

    5/2/25 8:00:00 AM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

    The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), including its Quell platform, positioning itself as a diversified, commercial-scale player in non-invasive health and wellness treatments. NURO is a commercial stage h

    12/17/24 4:05:00 PM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    NeuroMetrix to be Acquired by electroCore

    WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. ("NeuroMetrix" or the "Company") (NASDAQ:NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. ("electroCore") (NASDAQ:ECOR), a commercial stage bioelectronic medicine and wellness company, will acquire NeuroMetrix. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close late in the first quarter of 2025. Under the terms of the merger agreement, a subsidiary of electroCore will merge with NeuroMetrix and NeuroMetrix will become a wholly owned subsidiary of electroCore. The shareholders of NeuroMetrix will be entitled to

    12/17/24 4:05:00 PM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    $NURO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Horowitz Joshua returned 90,307 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeuroMetrix, Inc. (0001289850) (Issuer)

    5/5/25 6:51:59 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    Director Goodman David returned 7,602 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeuroMetrix, Inc. (0001289850) (Issuer)

    5/5/25 5:53:03 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    Director Van Avermaete David returned 7,601 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeuroMetrix, Inc. (0001289850) (Issuer)

    5/5/25 5:53:02 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    SEC Filings

    View All

    SEC Form 15-12G filed by NeuroMetrix Inc.

    15-12G - NeuroMetrix, Inc. (0001289850) (Filer)

    5/12/25 4:05:30 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by NeuroMetrix Inc.

    EFFECT - NeuroMetrix, Inc. (0001289850) (Filer)

    5/6/25 12:15:11 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by NeuroMetrix Inc.

    EFFECT - NeuroMetrix, Inc. (0001289850) (Filer)

    5/6/25 12:15:15 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    Financials

    Live finance-specific insights

    View All

    electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

    The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), including its Quell platform, positioning itself as a diversified, commercial-scale player in non-invasive health and wellness treatments. NURO is a commercial stage h

    12/17/24 4:05:00 PM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options

    WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations. In collaboration with a fina

    8/6/24 7:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

    WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024. For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be acce

    7/31/24 2:03:34 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    Leadership Updates

    Live Leadership Updates

    View All

    NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

    Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22 years of investing experience. Since January 2012, he has served as a portfolio manager with Palm Management (US) LLC. Mr. Horowitz also brings extensive public company board experience. Earlie

    4/19/24 8:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

    WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company's prescription wearable neurotherapeutics business in the U.S. market. The Company recently received FDA De Novo authorization to market its Quell® device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021. Mr. Harmel brings 15 years of experience in high growth medical technol

    9/1/22 9:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    NeuroMetrix Appoints Brad Fluegel to its Board of Directors

    WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022. Mr. Fluegel has a broad commercial and advisory background with concentrated industry experience in healthcare and medical technology. He has held numerous leadership roles over the past 25+ years, primarily in healthcare strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for leading all commercial healthcare activities, including sales and contracting, biopha

    6/28/22 9:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NeuroMetrix Inc.

    SC 13G - NeuroMetrix, Inc. (0001289850) (Subject)

    9/27/24 3:56:52 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by NeuroMetrix Inc. (Amendment)

    SC 13D/A - NeuroMetrix, Inc. (0001289850) (Subject)

    3/4/24 4:12:13 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by NeuroMetrix Inc.

    SC 13D - NeuroMetrix, Inc. (0001289850) (Subject)

    2/27/24 4:00:09 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care